Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luveltamab tazevibulin in platinum-resistant ovarian cancer
NCT05870748Phase 3Terminated
- Sponsor
- Sutro Biopharma, Inc.
- Start
- Jul 2023
- Primary completion
- Aug 2025
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 7
01
Overview
A Phase 3 trial of luveltamab tazevibulin in ovarian cancer, sponsored by Sutro Biopharma, Inc.. Started Jul 2023; status: terminated.
02
Drugs
luveltamab tazevibulin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05870748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05870748.